HALO earnings date and last-quarter result: last quarter beat, P/E 26.65. Updated 2026-07-23.
Halozyme Therapeutics (HALO) Research Hub
Halozyme Therapeutics (HALO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 128.01 USD (+1.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 26.65, market cap 9.32B. This hub links to the full technical, earnings and options research available for HALO.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 128.01 USD (+1.89%) |
| 52-week range | 68.18 USD – 128.11 USD |
| Trend regime | Range |
| 14-day RSI | 88.6 (Overbought) |
| Trailing P/E | 26.65 |
| Market cap | 9.32B |
| Dividend yield | 0.00% |
Available research for HALO
Covered Call on HALO: how it works, illustrative setup around the real 128.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on HALO: how it works, illustrative setup around the real 128.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on HALO: how it works, illustrative setup around the real 128.01 USD price, max profit/loss, breakeven and when to use it. Educational.
HALO technical analysis: range, last 128.01 USD, RSI 88.6, 52w range 68.18 USD–128.11 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is HALO in?
Halozyme Therapeutics (HALO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is HALO in an uptrend or downtrend?
As of 2026-10-26, HALO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is HALO's trailing P/E ratio?
HALO's trailing P/E is 26.65, with a market cap of 9.32B. See the earnings research page for full valuation detail.